STOCK TITAN

Vericel Corp - VCEL STOCK NEWS

Welcome to our dedicated news page for Vericel (Ticker: VCEL), a resource for investors and traders seeking the latest updates and insights on Vericel.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vericel's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vericel's position in the market.

Rhea-AI Summary
Vericel Corporation announces positive results from Phase 3 DETECT study on NexoBrid treatment for severe burns, with over 90% of patients achieving complete eschar removal and reduced need for surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.03%
Tags
-
Rhea-AI Summary
Vericel launches NexoBrid for eschar removal in burn patients, expanding market potential. NexoBrid offers faster and more precise removal of eschar, reducing need for skin grafting. Represents a paradigm shift in burn treatment. Market potential estimated at $300 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.14%
Tags
none
-
Rhea-AI Summary
Vericel Corporation's CEO to participate in fireside chat at Morgan Stanley Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.98%
Tags
conferences
Rhea-AI Summary
Vericel Corporation (NASDAQ:VCEL) reported a record second quarter total revenue of $45.9 million, with 24% growth versus the prior year. MACI revenue grew by 27% to $36.3 million, and Epicel revenue grew by 17% to $9.6 million. The full-year 2023 revenue guidance has been raised to $190-197 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.45%
Tags
conferences earnings
-
Rhea-AI Summary
Vericel Corporation reported record first-quarter total revenue of $41 million, with MACI revenue increasing by 32% to $34.2 million. Full-year 2023 revenue guidance has been raised to $184-$192 million. The company also highlighted positive business highlights, including the highest number of surgeons using MACI biopsies and progress on the NexoBrid program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.11%
Tags
Rhea-AI Summary
Dimension Inx announces the appointments of Paul K. Wotton, Ph.D., to the board of directors and Chris Ehrlich as Senior Advisor. Dr. Wotton brings expertise in platform growth opportunities and has experience leading biotechnology and pharmaceutical companies. Mr. Ehrlich will focus on corporate development and financial strategy. Dimension Inx is a biomaterials platform company developing therapeutics for tissue and organ restoration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.06%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.29%
Tags
Vericel Corp

Nasdaq:VCEL

VCEL Rankings

VCEL Stock Data

2.32B
44.66M
0.84%
112.24%
9.08%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Cambridge

About VCEL

about vericel founded in 1989, vericel (formerly aastrom biosciences), is dedicated to the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. the company markets two cell therapy products in the united states, carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee and epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. vericel is also developing maci, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-t, a patient specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (dcm). to fulfill vericel’s mission of helping people with severe diseases and conditions rea